Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CollabRx, Inc. (CLRX) And GeneInsight Announce Collaboration Agreement To Support Interpretation Of Genetic Sequencing

|Includes: CollabRx, Inc (CLRX)

CollabRx is a data analytics company focused on informing the clinical interpretation of molecular diagnostic testing. The cloud-based expert systems company aggregates and contextualizes knowledge on genomics-based medicine with specific insights for the country's top cancer experts.

The company today announced a collaboration agreement with GeneInsight to deliver a unique medical informatics solution to support the interpretation and reporting of genetic variants from sequencing-based clinical laboratory tests. GeneInsight LLC is a developer of software to support knowledge management and reporting for genetic testing laboratories. Since 2005, it has supported the reporting workflow and interpretation of more than 30,000 clinical genetic tests.

Under the terms of the agreement, CollabRx medical and scientific content will be made available through the GeneInsight knowledge management platform. The collaboration will initially focus on oncology with the combined offering accessible to the clinical laboratory market. These laboratories will be able to catalog genetic variants from sequencing-based tests and tie them to CollabRx's curated knowledge on available drugs and clinical trials.

This partnership is a big step toward enabling a truly integrated clinical laboratory workflow. One of the biggest challenges facing clinicians is organizing and clinically interpreting genetic sequence data, which would help improve patient care. This is especially true in cancer care. For additional information about CollabRx and this agreement with GeneInsight, please visit collabrx.com.

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net